A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Trial Profile

A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Fedratinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Sep 2014 New drug dosage of 300 mg has been added to treatment as reported by ClinicalTrials.gov.
    • 09 Jan 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2014.
    • 18 Nov 2013 Status changed from recruiting to discontinued, according to a Sanofi media release. Development of fedratinib has been discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top